Johnson & Johnson is at the forefront of healthcare innovation, particularly in the fields of medicine and medical technology. Their Innovative Medicine division focuses on developing science-based treatments that address complex diseases such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The company emphasizes the importance of patient input in shaping their research and development efforts, which has led to advancements in therapies that leverage the immune system to improve patient outcomes. Additionally, Johnson & Johnson is committed to addressing health disparities, particularly in communities disproportionately affected by diseases like multiple myeloma, through initiatives like the That’s My Word® campaign, which aims to raise awareness and improve access to treatment for underrepresented populations.

In the realm of medical technology, Johnson & Johnson MedTech is dedicated to creating innovative solutions that enhance surgical precision and patient care. Their focus on less invasive and more personalized treatments is evident in their work on interventional solutions, orthopedics, and surgical devices. The company has developed advanced tools for stroke treatment, including the Cerenovus Stroke Solutions™, which aim to improve the efficiency and effectiveness of clot removal procedures. By investing in research and clinical trials, Johnson & Johnson is not only advancing treatment options but also striving to ensure that these innovations are accessible to a broader range of patients, thereby improving overall health outcomes and quality of life.

United States

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. 

Cancer

Cardiovascular Diseases

Central Nervous System (CNS)

Eye Diseases

Immune System Diseases

Johnson & Johnson 

Multiple myeloma

DARZALEX (daratumumab)

CARVYKTI (ciltacabtagene autoleucel)

Urothelial cancer

BALVERSA (erdafitinib)

Pulmonary arterial hypertension

OPSUMIT (macitentan)

UPTRAVI (selexipag)

Treatment Resistant Depression

SPRAVATO (esketamine)

Ulcerative colitis

TREMFYA (guselkumab) 

Non-small cell lung carcinoma

RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib)

Psoriasis

Chronic lymphocytic leukemia

IMBRUVICA (ibrutinib) 

TALVEY (talquetamab)

Castration-resistant prostate cancer

AKEEGA (niraparib/abiraterone)

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

Autoimmune disease

Myasthenia gravis

Nipocalimab is an investigational, high-affinity, fully human, aglycosylated, effectorless, monoclonal antibody that aims to selectively block FcRn to reduce levels of circulating immunoglobulin G (IgG) antibodies, including autoantibodies and alloantibodies that underlie multiple conditions.7 Nipocalimab is the only anti-FcRn being studied across three key segments in the autoantibody space: Rare Autoantibody (e.g., generalized myasthenia gravis in adults and children, chronic inflammatory demyelinating polyneuropathy, warm autoimmune hemolytic anemia, and idiopathic inflammatory myopathies); Maternal Fetal diseases mediated by maternal alloantibodies (e.g., HDFN); and Prevalent Rheumatology (e.g., rheumatoid arthritis, SjD, and systemic lupus erythematosus)8-15 Blockade of FcRn has the potential to reduce overall autoantibody levels while preserving immune function without causing broad immunosuppression. Blockade of IgG binding to FcRn in the placenta is also believed to prevent transplacental transfer of maternal alloantibodies to the fetus.

IMAAVYTM (nipocalimab-aahu)

TECVAYLI® (teclistamab-cqyv)

DARZALEX&nbsp;FASPRO®&nbsp;(daratumumab and hyaluronidase-fihj)&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4264821-1&amp;h=9359001&amp;u=https%3A%2F%2Fwww.janssen.com%2Fus%2Fsites%2Fwww_janssen_com_usa%2Ffiles%2Fdarzalex_faspro_approval_press_release_final.pdf&amp;a=received" rel="nofollow" target="_blank">received</a>&nbsp;U.S. FDA approval in May 2020 and is approved for nine indications in multiple myeloma, four of which are for frontline treatment in newly diagnosed patients who are transplant eligible or ineligible.14&nbsp;It is the only subcutaneous CD38-directed antibody approved to treat patients with MM. DARZALEX&nbsp;FASPRO®&nbsp;is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) + lenalidomide 

Smoldering Multiple Myeloma (SMM)

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) received U.S. FDA approval in May 2020 and is approved for nine indications in MM, four of which are for frontline treatment in newly diagnosed patients who are transplant eligible or ineligible.3,6 It is the only subcutaneous CD38-directed antibody approved to treat patients with MM. DARZALEX FASPRO® is co-formulated with recombinant human hyaluronidase PH20, Halozyme's ENHANZE® drug delivery technology.

OPSUMIT (macitentan) w/tadalafil FDC

Non-muscle invasive bladder cancer

TAR-200 is an investigational targeted releasing system designed to provide controlled release of gemcitabine into the bladder, sustaining local drug exposure for weeks at a time. The safety and efficacy of TAR-200 are being evaluated in Phase 2 and Phase 3 studies in patients with muscle-invasive bladder cancer (MIBC) in SunRISe-2 and SunRISe-4 and non-muscle-invasive bladder cancer (NMIBC) in SunRISe-1 and SunRISe-3.

TAR-200 (RIS/gemcitabine plus cetrelimab)

DARZALEX FASPRO® + bortezomib, lenalidomide & dexamethasone (D-VRd) 

RYBREVANT (amivantamab) + Chemotherapy

Crohns disease

TREMFYA (guselkumab)

Sjögren-Larsson Syndrome

Nipocalimab​ 

Atrial fibrillation

The VARIPULSE™ Platform is Biosense Webster’s Irreversible Electroporation ablation system. The fully integrated platform includes the VARIPULSE™ Catheter, TRUPULSE™ Generator, and CARTO™ 3 Mapping System VARIPULSE™ Service Pack Software. In January 2024, Biosense Webster announced that the VARIPULSE™ Platform received its first regulatory approval from the Japan Ministry of Health, Labour and Welfare for the treatment of symptomatic drug refractory recurrent paroxysmal AFib using PFA. In the U.S., the VARIPULSE™ Catheter and TRUPULSE™ Generator are currently investigational and are not approved by FDA. In Europe, the TRUPULSE™ generator received CE mark in late 2023 and the VARIPULSE™ Catheter received CE mark in February 2024.

VARIPULSE™

Icotrokinra (JNJ-2113)

Solid tumor/s

Rheumatoid arthritis

nipocalimab​

Warm autoimmune hemolytic anemia

nipocalimab​ 

Atopic dermatitis

Skin disease/disorder

NM26, which is ready to enter Phase 2 studies, targets two clinically proven pathways, IL-4R alpha subunit (IL-4Rα) and IL-31, in atopic dermatitis (AD). Atopic dermatitis, the most common inflammatory skin disease3, is highly heterogeneous with different disease-driving mechanisms in distinct patient subpopulations. NM26 targets IL-4Rα, which triggers Th2-mediated skin inflammation4, and IL-31, which impacts skin itch and subsequent scratching that worsen the disease5. In addition to potentially transforming the standard of care for AD, NM26 could also be efficacious in other inflammatory skin diseases involving Th2 inflammation and itch.

NM26

RYBREVANT® (amivantamab-vmjw), a fully-human bispecific antibody targeting EGFR and MET with immune cell-directing activity, is approved in the U.S., Europe, and in other markets around the world as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.3 In the subcutaneous formulation, amivantamab is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology. RYBREVANT® is also approved in the U.S. in combination with chemotherapy (carboplatin and pemetrexed) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test. In October 2023, a type II extension of indication application was submitted to the European Medicines Agency (EMA) seeking approval of RYBREVANT® for this indication.

RYBREVANT ( SC amivantamab) + lazertinib)

Muscle-invasive bladder cancer

TAR-200 (RIS/gemcitabine plus cetrelimab) 

RYBREVANT (intravenous)

Nipocalimab​

TAR-210 is an investigational targeted releasing system designed to provide controlled release of erdafitinib into the bladder. The safety and efficacy of TAR-210 is being evaluated in a Phase 1 study in patients with MIBC and NMIBC

Johnson & Johnson

Company Details